What is ACRS stock price today?

ACRS (Aclaris Therapeutics Inc) stock is trading at $4.41 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACRS stock going up or down today?

ACRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACRS stock now?

The decision to buy ACRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACRS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACRS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ACRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ACRS's P/E ratio?

P/E ratio data for ACRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ACRS's market cap?

ACRS (Aclaris Therapeutics Inc) has a market capitalization of $0.63 billion, making it a small-cap stock.

What is ACRS's price to book ratio?

ACRS trades at a price-to-book (P/B) ratio of 4.21, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ACRS pay dividends?

ACRS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACRS's dividend yield?

ACRS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACRS stock a good long-term investment?

ACRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACRS's revenue growth rate?

ACRS has shown revenue growth of 0.4% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ACRS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ACRS?

Key risks for ACRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACRS compare to its competitors?

Compare ACRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACRS's performance and positioning.

What is ACRS's stock price target for 2026?

Our AI model provides price targets for ACRS based on fundamental analysis: Bull case $5.73 (+30%), Base case $5.07 (+15%), Bear case $3.97 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACRS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACRS's next earnings report?

ACRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACRS - Aclaris Therapeutics Inc

NYSE * Healthcare * Biotechnology

$4.41

$-0.30 (-6.37%)

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Price Chart

Loading chart...

ACRS Key Statistics

Market Cap

$625.69M

P/B Ratio

4.21

EPS

$-0.56

Revenue Growth

+0.4%

Employees

How ACRS Compares to Peers

ACRS has the fastest revenue growth among competitors

ACRS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACRS(This stock)	$625.69M	N/A	0%	0.0%	-
AMGNAmgen Inc	$186.52B	24.0	0%	0.2%	vs AMGN
GILDGilead Sciences	$160.39B	17.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.12B	26.2	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$66.84B	15.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$29.00B	21.1	0%	0.1%	vs BIIB

Aclaris Therapeutics Inc Company Information

Headquarters: 701 Lee Road, Wayne, PA, United States, 19087, undefined
Website: www.aclaristx.com
Sector: Healthcare
Industry: Biotechnology

ACRS - Aclaris Therapeutics Inc

About Aclaris Therapeutics Inc

Price Chart

ACRS Key Statistics

How ACRS Compares to Peers

Aclaris Therapeutics Inc Company Information

ACRS Lician Score

ACRS Financial Snowflake

Upcoming Events for ACRS